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Editorial
Reperfusion in women with STEMI: a date not to be late!
Reperfusão em mulheres com IAMCST: um encontro para não chegar atrasado!
“You may delay, but time will not”
Benjamin Franklin
Results from large studies investigating clinical outcomes follow-
ing ST-elevation myocardial infarction (STEMI) have suggested that 
outcomes are worse in women in comparison to men,1 regardless of 
the reperfusion strategy employed. The majority of these observa-
tions, however, have been based upon results from large clinical tri-
als in which women have only made up 20 to 30% of the total study 
population.2-4 A number of explanations have been postulated for 
the worse outcomes in women, including older mean age at presen-
tation, several comorbidities, more extended coronary artery dis-
ease, late presentation, and delays in diagnosis.5,6 Nonetheless, 
specific independent predictors for poor response to reperfusion 
therapy and therefore clinical outcomes in women are poorly de-
fined; moreover, following multivariable adjustment for baseline 
confounders, in several studies mortality was not statistically differ-
ent between men and women.7
In this issue of the Revista Brasileira de Cardiologia Invasiva, 
Sousa et al. reported the results of a retrospective analysis of 327 
women presenting with STEMI treated with thrombolysis as first-
line treatment.8 They reported clinical outcomes of women who 
achieved successful reperfusion following lysis compared to those 
who did not and required rescue angioplasty. Additionally, they at-
tempted to identify independent predictors for lysis failure in this 
patient group. Out of the total cohort of 1,261 patients in the regis-
try, 327 (26%) were women and were treated with thrombolysis and 
early catheterization following successful reperfusion (n = 206) or 
rescue angioplasty for failed lysis (n = 121). There were no differ-
ences in baseline characteristics between groups, which included 
women with a large percentage of cardiovascular risk factors, such 
as smoking history, dyslipidemia, and hypertension. A few general 
observations should be made. Firstly, in women presenting with 
STEMI who cannot be treated with the gold standard treatment of 
primary angioplasty in a timely manner, the administration of con-
temporary thrombolysis regimens is safe, with only one occurrence 
of hemorrhagic stroke in each group reported in this patient cohort. 
Secondly, this representative “all-comer” population demonstrated 
that, in support of previous observations,3 lysis failed in approxi-
mately one-third of women presenting with STEMI, resulting in 
clinical outcomes that were significantly worse (in-hospital mortal-
ity 22% vs. in 2.5%; p < 0.001), supporting the practice of transferring 
patients to angioplasty-capable centers following administration of 
lysis to facilitate emergency rescue angioplasty if required. Finally, 
as expected, patients who failed lysis had lower prevalence of post-
percutaneous coronary intervention (PCI) Thrombolysis in Myocar-
dial Infarction (TIMI) flow 2 or 3 and post-PCI myocardial blush 2 or 
3, with subsequent significantly worse ejection fraction and higher 
incidence of heart failure when compared to patients that achieved 
successful reperfusion. Specifically, with regards to predicting lysis 
failure, the authors identified pain-to-needle time greater than 3 
hours, Zwolle Risk Score (which includes ischaemic time as contrib-
uting component), and presence of renal dysfunction as independent 
predictors in women, in support of findings applicable to the popu-
lation as a whole.
However, it is necessary to consider that some limitations apply 
to this study. First, as in every retrospective analysis, the findings 
are subject to confounder bias. Second, the small sample size of the 
study population, and therefore low statistical power, precludes an 
adequate multivariable adjustment and detection of other covari-
ates independently associated with the need for rescue PCI. Third, 
important procedural and angiographic variables, such as antiplate-
let and anticoagulant treatment, arterial access site, infarct location, 
and culprit artery characteristics were not reported, therefore limit-
ing the interpretation of the severely impaired outcomes associated 
with rescue PCI. 
Notwithstanding these limitations, the present study under-
scores the importance of “time” in the current STEMI practice in a 
female Brazilian population. Both pain-to-needle time and Zwolle 
Risk Score were strong predictors of lysis failure in women. Previous 
data suggest that every minute of delay in treatment of patients with 
STEMI has a significant effect on mortality after both thrombolytic 
and primary PCI reperfusion.9 Female gender has been constantly 
associated with delayed presentation, reperfusion, and undertreat-
ment.7,10,11 Moreover, STEMI in women demonstrated to be associat-
ed with worse outcomes when compared with males. Several 
distinct mechanisms might explain the greater effect of STEMI on 
mortality in women: (i) the higher risk for bleeding complications, 
whose subsequent impact on morbidity and mortality has been well 
described;12 (ii) a more adverse clinical risk profile at baseline when 
compared with males;1 and (iii) the greater burden of myocardial in-
jury and necrosis with secondary higher risk of negative myocardial 
remodelling and death for heart failure when compared with 
males.13 A substudy from the HORIZONS-AMI (Harmonizing Out-
comes with Revascularization and Stents in Acute Myocardial In-
farction) trial reported higher in-hospital, 30-day, and 3-year major 
adverse cardiac events (MACE) and bleeding in women compared 
with men after STEMI.12 However, in that study, after multivariable 
adjustment for baseline and procedural confounders, there were no 
differences in mortality between genders.12 Stronger evidence has 
been also provided by a large gender-based meta-analysis that in-
cluded over 18,000 women and reported higher in-hospital and 
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1 year mortality in women after STEMI.14 The multiplicative effect 
between STEMI and female gender on mortality might therefore be 
further independently accentuated by presentation delay.
With these data in mind, how can we improve women’s cardio-
vascular health and early recognition and prognosis of acute myo-
cardial infarction? A first step would be a community-based action 
to increase the awareness of the prevalence, incidence, and impor-
tance of cardiovascular diseases among the female population 
through patient education, public health initiatives, and efforts in 
promote cardiovascular research in women.11 Cardiovascular dis-
ease in women are often underdiagnosed and undertreated.11 The 
study of Sousa et al. suggests the presence of this issue in a Brazilian 
population.8 A collaboration to uniformly change the perception, at 
a physician- and patient-level, is therefore of paramount importance 
in order to improve cardiovascular women’s health.
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